Dr. Porcu on the Need for Diverse Representation in Clinical Trials


In Partnership With:

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Pierluigi Porcu, MD, professor, director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Jefferson Health, Sidney Kimmel Medical College, discusses the need for diverse representation in clinical trials.

The end goal of cancer research is to find better mechanisms for treatment delivered through more effective and safer drugs, Porcu says. The purpose of clinical trials is to test new drugs in ways that are going to be meaningful in the real world, making it important to include large, diverse populations to better replicate patient populations who are treated outside of clinical trials, Porcu explains.

However, this has been a challenge because enrollment in clinical trials features with many obstacles and barriers, leading to some trial populations to not being representative of the real world, Porcu continues. This poses challenges in determining if treatments are equally effective across different populations, Porcu concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD